Governance Neurocrine Biosciences, Inc.

NBIX

US64125C1099

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 09:27:23 11/07/2025 pm IST			5-day change	1st Jan Change
133.76 ^USD	-0.86%		+4.79%	-1.83%

09/07	UBS Adjusts Price Target on Neurocrine Biosciences to $174 From $152, Maintains Buy Rating	MT
07/07	RBC Raises Price Target on Neurocrine Biosciences to $146 From $145, Keeps Outperform Rating	MT

Executive Committee: Neurocrine Biosciences, Inc.

Manager

Positions heldSince

Kyle Gano

52 year

Chief Executive Officer	11/10/2024
President	11/10/2024

Matthew Abernethy

46 year

Director of Finance/CFO

01/11/2017

Ingrid Delaet

59 year

General Counsel

01/01/2021

Jude Onyia

61 year

Chief Tech/Sci/R&D Officer

30/11/2021

Todd Tushla

Investor Relations Contact

01/09/2019

Julie Cooke

58 year

Human Resources Officer

01/09/2017

Darin Lippoldt

60 year

General Counsel	01/10/2014
Corporate Secretary	01/10/2014

Bill Wilson

Chief Operating Officer	01/03/2004
Chief Tech/Sci/R&D Officer	01/09/1996

Sanjay Keswani

55 year

Chief Tech/Sci/R&D Officer

02/06/2025

Composition of the Board of Directors: Neurocrine Biosciences, Inc.

Director

CommitteesSince

William Rastetter

77 year

Audit Committee	21/01/2015
Compensation Committee Chair	11/07/2019

Christine Poon

72 year

Executive Committee	01/09/2006
Finance Committee Chair
Governance Committee	06/02/2024
Compensation Committee Chair	16/11/2010
Finance Committee	05/05/2011
Audit Committee	12/02/2024
Nominating Committee	06/02/2024

George Morrow

73 year

Governance Committee	01/11/2015
Nominating Committee	01/11/2015
Compensation Committee Chair	02/07/2009
HR Committee Chair	01/02/2006
Compensation Committee	01/11/2015

Shalini Sharp

50 year

Compensation Committee	01/01/2024
Audit Committee Chair	01/01/2024
Governance Committee	16/01/2025
Nominating Committee	16/01/2025

Leslie Norwalk

59 year

Audit Committee	24/07/2019
Governance Committee Chair
Nominating Committee Chair

Stephen Sherwin

76 year

Audit Committee	09/12/2011
Finance Committee	01/01/2010

Richard Pops

63 year

Compensation Committee Chair	01/04/1998
Finance Committee	01/09/2011

Johanna Mercier

55 year

Governance Committee	15/04/2021
Nominating Committee	15/04/2021

Kevin Gorman

67 year

Compensation Committee	14/04/2017
HR Committee	14/04/2017

Gary Lyons

74 year

Director/Board Member	01/02/1993
Independent Dir/Board Member	01/01/2008

Kyle Gano

52 year

Director/Board Member

11/10/2024

Latest Appointments: Neurocrine Biosciences, Inc.

Neurocrine Biosciences Names Lewis Choi as Chief Information Officer	10/06	MT
Neurocrine Biosciences Appoints Lewis Choi As Chief Information Officer	10/06	RE
Neurocrine Biosciences, Inc. Announces the Appointment of Lewis Choi as Chief Information Officer, Effective June 9, 2025	10/06	CI
Neurocrine Biosciences Appoints New Chief Medical Officer	04/04	MT
Neurocrine Biosciences Appoints Dr. Sanjay Keswani As Chief Medical Officer	04/04	RE
Neurocrine Biosciences Appoints Sanjay Keswani as Chief Medical Officer, Effective June 2, 2025	04/04	CI
Andrew Ratz Joins Neurocrine Biosciences, Inc. as Senior Vice President of Drug Development, Delivery and Device	24/01	CI

More news

Former Officers and Directors: Neurocrine Biosciences, Inc.

Insider

Positions held

SinceUntil

Eiry Roberts

Chief Tech/Sci/R&D Officer

08/01/2018

02/06/2025

David Boyer

Corporate Officer/Principal

30/09/2019

11/12/2024

Malcolm Lloyd-Smith

General Counsel

01/09/2014

01/04/2023

Dimitri Grigoriadis

Chief Tech/Sci/R&D Officer	01/01/2013	01/01/2023
Corporate Officer/Principal	01/01/1993	01/01/2013

Brenda Van Vreeswyk

Human Resources Officer

01/02/2016

01/09/2022

Alfred Sandrock

Director/Board Member	03/09/2015	19/05/2020
Independent Dir/Board Member	03/09/2015	19/05/2020

Ebun Garner

Corporate Officer/Principal

01/03/2017

01/04/2019

Corinne Nevinny

Director/Board Member	01/06/2004	22/09/2018
Independent Dir/Board Member	01/06/2004	22/09/2018

Christopher Flint O'Brien

Chief Tech/Sci/R&D Officer

01/01/2005

08/01/2018

David-Alexandre Gros

Chief Operating Officer	06/01/2017	31/12/2017
Director of Finance/CFO	06/02/2017	31/12/2017
President	06/01/2017	31/12/2017

Joseph A. Mollica

Director/Board Member	24/02/2012	17/10/2017
Chairman	01/06/1997	24/02/2012
Independent Dir/Board Member	01/06/1997	17/10/2017

Daljit Singh Aurora

Corporate Officer/Principal

01/05/2015

01/07/2016

Ajay Madan

Corporate Officer/Principal

01/02/2013

01/07/2016

W. Thomas Mitchell

Director/Board Member	01/11/2002	20/05/2016
Independent Dir/Board Member	09/12/2011	20/05/2016

Yun Fei Zhu

Corporate Officer/Principal

01/01/1997

01/05/2009

Stephen Betz

Corporate Officer/Principal

01/06/2003

01/05/2009

Patricia Lady

Comptroller/Controller/Auditor	01/01/2007	01/01/2009
Director of Finance/CFO	01/01/2007	01/01/2009

Chrysa Mineo

Corporate Officer/Principal

01/01/1997

01/01/2009

Richard Ranieri

Chief Administrative Officer	01/02/2008	01/08/2008
Human Resources Officer	01/06/2005	01/08/2008

Carol A. Baum

Sales & Marketing

01/03/2003

01/02/2008

Zachary Hornby

Corporate Officer/Principal

01/06/2006

01/01/2008

Scott Struthers

Director/Board Member	01/01/1998	01/01/2008
Corporate Officer/Principal	01/01/1998	01/01/2008

Stefan Proniuk

Corporate Officer/Principal

01/01/2008

Paul W. Hawran

Director of Finance/CFO	01/04/2007	01/04/2007
Founder	01/01/1993	01/04/2007

Adrian Adams

Director/Board Member

05/01/2005

14/02/2007

Niel C. Hoglen

Corporate Officer/Principal

01/01/2007

Wendell Wierenga

Chief Tech/Sci/R&D Officer

01/07/2004

01/12/2006

Henry Y. Pan

Chief Tech/Sci/R&D Officer

01/10/2001

02/06/2006

Yang Sai

Corporate Officer/Principal

01/01/2001

William Mccarthy

Corporate Officer/Principal

01/01/2005

01/01/2006

Robert J. Little

Corporate Officer/Principal

01/01/2003

01/01/2006

Lawrence Steinman

Director/Board Member	01/01/1997	01/01/2005
Founder	01/01/1997	01/01/2005

Thomas J. Joyce

Sales & Marketing

01/04/2002

01/01/2004

Michelle Martin

Comptroller/Controller/Auditor

01/01/2003

Stefen A. Boehme

Corporate Officer/Principal

01/01/1995

01/01/2003

Tim Coughlin

Director of Finance/CFO

01/09/2006

Barbara M. Finn

General Counsel

01/10/2000

Stephen G. Marcus

General Counsel

01/12/1997

01/09/1999

Errol de Souza

Director/Board Member	01/10/1992	01/08/1998
Chief Tech/Sci/R&D Officer	01/10/1992	01/08/1998
Founder	01/01/1992	01/08/1998

John W. Beck

Director of Finance/CFO

01/02/1994

01/04/1998

Margaret E. Valeur-Jensen

General Counsel	01/01/1998	-
Corporate Secretary	01/01/1998	-

Haig P. Bozigian

Corporate Officer/Principal

Howard Birndorf

Director/Board Member

01/01/1992

01/01/1997

Wylie W. Vale

Director/Board Member	01/09/1992	-
Founder	01/09/1992	-
Independent Dir/Board Member	01/09/1992	-

Derek Chalmers

Corporate Officer/Principal

Paul J. Conlon

Chief Tech/Sci/R&D Officer

John Saunders

Chief Tech/Sci/R&D Officer

Navjot Rai

Investor Relations Contact	-	-
Public Communications Contact	-	-

Jane Sorensen

Investor Relations Contact

Alan C. Foster

Corporate Officer/Principal

Cynthia J. Thomas

Human Resources Officer

Pia Lindström

General Counsel

Chen Chen

Corporate Officer/Principal

Tilman Oltersdorf

Corporate Officer/Principal

David Schnell

Director/Board Member

Gregory S. Naeve

Corporate Officer/Principal

Kevin B. Bacon

Corporate Officer/Principal

Scott Eliasof

Corporate Officer/Principal

Murray C. Maytom

Corporate Officer/Principal

David Campbell

Corporate Officer/Principal

Jason Zhang

Corporate Officer/Principal

Jeffrey P. Whitten

Corporate Officer/Principal

Douglas Bakan

Corporate Officer/Principal

Brian Rosenberger

Sales & Marketing

Age distribution of managers

Parity Men Women

Male	15
Female	5

Of which Executive Committee

Male	8
Female	1

Of which Directors

Male	7
Female	4

Revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

Revenue revisions (1 month)

EPS revisions (1 year)

EPS revisions (4 months)

ESG MSCI

ESG

Environment

Social

Governance

Controversy

Ethical controversies

Human rights controversies

Tax subsidies controversies

Sharia compliant

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntingtonâs disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.

Employees

1,800

Sector

Pharmaceuticals

Calendar

31/07 - Q2 2025 Earnings Release

More about the company